Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10819
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDonnan, Geoffrey Aen
dc.date.accessioned2015-05-16T00:23:30Z
dc.date.available2015-05-16T00:23:30Z
dc.date.issued1991-10-21en
dc.identifier.citationMedical Journal of Australia; 155(8): 563-71en
dc.identifier.govdoc1943940en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10819en
dc.description.abstractTo assess the current status and future directions of therapy in cerebrovascular disease.English language literature search using MEDLINE, Index Medicus, reviews, texts and relevant papers.Information has been drawn from approximately 200 articles.Those articles with most relevance to current practice and future directions in the therapy of cerebrovascular disease have been cited.Much progress has been made over the last 30 years in the therapy of primary and secondary prevention of cerebrovascular disease. The introduction of antihypertensive agents has been largely responsible for the decline in mortality from stroke and, in some areas, the incidence. Anticoagulants such as warfarin protect against ischaemic stroke in patients with mitral or aortic valve disease and/or atrial fibrillation. Antiplatelet agents are clearly effective in the secondary prevention of ischaemic stroke after transient ischaemic attacks; the risk of stroke or death is reduced, on average, by 22%. In patients with subarachnoid haemorrhage, ischaemic complications caused by vasospasm are reduced by calcium channel blockers. A new wave of therapies is now on the horizon to minimise tissue damage in the early stages of ischaemic stroke ("tissue rescue") with the introduction of thrombolytic agents, calcium channel blockers, NMDA antagonists and haemodilution techniques and many of these are currently being subjected to clinical trial. If they prove to be effective, our current management of acute ischaemic stroke may alter dramatically.en
dc.language.isoenen
dc.subject.otherAge Factorsen
dc.subject.otherAnticoagulants.therapeutic useen
dc.subject.otherAspirin.therapeutic useen
dc.subject.otherCerebral Infarction.drug therapy.etiologyen
dc.subject.otherCerebrovascular Disorders.drug therapy.prevention & controlen
dc.subject.otherForecastingen
dc.subject.otherHumansen
dc.subject.otherIschemic Attack, Transient.drug therapy.prevention & controlen
dc.subject.otherPlatelet Aggregation Inhibitors.therapeutic useen
dc.subject.otherRisk Factorsen
dc.subject.otherSubarachnoid Hemorrhage.drug therapy.prevention & controlen
dc.titleTherapy in cerebrovascular disease: current status and future directions.en
dc.typeJournal Articleen
dc.identifier.journaltitleMedical Journal of Australiaen
dc.identifier.affiliationDepartment of Neurology, Austin Hospital, Heidelberg, VIC.en
dc.description.pages563-71en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1943940en
dc.type.austinJournal Articleen
local.name.researcherDonnan, Geoffrey A
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.